Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease

20 May 2019

Abstract excerpt

Parkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons in the substantia nigra. A characteristic pathological feature of PD is cytoplasmic accumulation of α-synuclein (SNCA) protein. Multiplication of the SNCA gene in familial PD and pathological accumulation of SNCA protein during progression of sporadic PD suggest that increased SNCA protein levels increase the risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments
Share to RNA regulation and disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31110191
DOI: 10.1038/s41598-019-43772-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s diseasePMID 31110191Read ↗

Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA geneSemantic proximity Read ↗

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s diseaseSemantic proximity Read ↗

In vivo silencing of alpha-synuclein using naked siRNASemantic proximity Read ↗

Nucleic Acid-Based Theranostics for Tackling Alzheimer's DiseaseSemantic proximity Read ↗

The m6A RNA methylation exerts a neuroprotective function by regulating the expression of α-synucleinSemantic proximity Read ↗

Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatmentSemantic proximity Read ↗

Antisense Drugs Make Sense for Neurological DiseasesSemantic proximity Read ↗

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disordersSemantic proximity Read ↗

<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse modelSemantic proximity Read ↗

The expanding application of antisense oligonucleotides to neurodegenerative diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.